Neoantigen and target discovery for the therapies you are building
myNEO Therapeutics is an AI-driven immunotherapy company. We collaborate with vaccine, T-cell, and biologics teams to find the immune targets their programs need. From there we help with design, analysis, and visualization of what comes next. The aim is safer, more effective immune-based therapies alongside shorter preclinical development timelines.
The company behind the solutions
myNEO started in Ghent in 2018, founded by Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge. The idea was simple: find better immune targets, and optimize the design, analysis, and visualization that turns those targets into clinical programs. Our multidisciplinary team, board, and advisors has deep expertise in immunology, oncology, and data science and is dedicated to break the boundaries of target discovery and bring stronger targets to the clinic. Come build it with us.
Meet the team →Built for the teams designing immune therapies
Start from the path that matches your program: biologics, vaccines and T-cell therapies, or partnered assets.
For biologics developers
Discover differentiated, high-confidence targets and de-risk immunogenicity for antibody, ADC, and cell-therapy programs.
See biologics solutions →
For vaccine & T-cell developers
Unlock precise, high-immunogenic antigen discovery for immune-driven therapies.
See vaccine solutions →
For strategic partners
Explore our proprietary asset library of high-confidence immunotherapy targets, including camyotopes, available for partnering and licensing.
View pipeline and assets →A modular suite for immune-driven discovery and design
Each solution can be used independently or combined into an integrated end-to-end workflow.
myNEO – Personalized neoantigen discovery
AI-powered, IVD-ready personalized neoantigen discovery for vaccine and T-cell programs
myCONSTRUCT – Construct design
Computational construct design enhancing expression and functional performance
mySHARED – Shared MHC-bound target discovery
AI-powered discovery of shared MHC-bound targets for off-the-shelf immunotherapeutic modalities.
myRNA – Codon optimization
Advanced codon optimization engine improving stability and translational efficiency.
mySURFACE – Surfaceome target discovery
AI-powered identification of surface antigens for biologics programs.
myADA – ADA risk prediction
Anti-Drug Antibody risk prediction enabling rational, data-driven biologics engineering.
mySELF – Autoimmune target discovery
AI-powered discovery for autoimmune therapeutic design.
myEPITOPE – Immunogenicity screening
Accurate epitope immunogenicity prediction derisking preclinical validation.
myPATHOGEN – Infectious target discovery
AI-powered discovery of pathogen-derived targets for infectious-disease programs.
myINSIGHTS – Large data analysis
Large dataset analysis supporting biomarker identification, response prediction, and decisions.
Antigen and neoantigen discovery
ImmunoEngine is myNEO's antigen discovery pipeline. It identifies tumor-specific antigens from whole-genome sequencing and ranks by variant quality, MHC presentation, and immunogenicity.
WGSBeyond SNVs and indels
Most neoantigen pipelines stop at SNVs and indels. Through analysis of whole-genome sequencing we also capture transposable elements, introns, gene fusions, and camyotope dark-genome targets, which is especially valuable in low-TMB tumors.
Variant qualityScore the event, not only the peptide
Each genomic event is scored for tumor specificity, clonality, prevalence, and expression. We keep ranking tied to variants that are real, clonal, and actually expressed in the tumor.
Peptide scorePresentation and immunogenicity
At peptide level, neoMS models the full MHC presentation pathway and neoIM predicts CD8 and CD4 T-cell immunogenicity. Together they rank antigens that can reach the cell surface and elicit a T-cell response.
Published methods behind the work
We publish peer-reviewed immunotherapy and antigen-discovery scientific papers, dedicated technology papers covering myADA, myEPITOPE, myCONSTRUCT, and mySELF, and whitepapers that go deeper into specific target classes and open questions in the field.
Top questions, answered
Short answers on who we are, what we build, and how teams work with us.
What is myNEO Therapeutics?
myNEO Therapeutics is a Ghent-based, AI-driven biotechnology company for antigen discovery, neoantigen discovery, and immune-target design. Its ImmunoEngine platform and modular solutions support vaccine, T-cell, biologics, and other immune-driven developers across antigen discovery, immunogenicity prediction, construct design, codon optimization, and translational data analysis.
Who does myNEO Therapeutics work with?
myNEO works with cancer vaccine developers, T-cell therapy developers, biologics and antibody developers, infectious disease vaccine groups, pharmaceutical companies, and academic research teams. Its solutions support target discovery and prioritization, product design, immunogenicity de-risking, and large-scale translational data analysis across therapeutic modalities and disease areas.
What is ImmunoEngine?
ImmunoEngine is myNEO's antigen discovery pipeline. It identifies tumor-specific antigens from whole-genome sequencing, including camyotope dark-genome targets, predicts MHC presentation with neoMS, scores immunogenicity with neoIM, and ranks the resulting candidates.
What is antigen discovery?
Antigen discovery identifies which proteins or peptides the immune system can recognize. At myNEO, ImmunoEngine performs antigen discovery and neoantigen discovery from whole-genome data, then ranks candidates for vaccine, T-cell, and other immune-driven programs.
Does myNEO do neoantigen discovery?
Yes. ImmunoEngine performs antigen discovery and neoantigen discovery for personalized and shared immunotherapy programs. Dedicated solutions then cover surface targets, immunogenicity, construct design, and analysis.
What problems does myNEO help solve?
myNEO addresses the target-selection bottleneck in immunotherapy: most computationally predicted targets never trigger a T-cell response. Its solutions identify which epitopes are presented and immunogenic, find shared and surface targets, reduce anti-drug antibody risk, and design multi-epitope constructs and mRNA sequences.
Can myNEO solutions be used independently?
Yes. Each solution can be used independently for a defined task or project, or multiple solutions can be combined into an integrated workflow based on the needs of the customer.
Talk to our team
Looking for a dedicated solution, a customized project, or a partnership? Our team can help.